

Biosketch Sept. 2023 – Distinguished Prof. Michel L. TREMBLAY PhD, F.R.S.C., C.Q.



Michel L. Tremblay is a Distinguished McGill Professor in the Department of Biochemistry and at the Goodman Cancer Institute. He is also an Associate member of the depts of Oncology, Microbiology & Immunology, and Medicine at McGill University. He **holds the Jeanne and Jean-Louis Lévesque Chair in Cancer Research** at McGill University. He completed his graduate studies at the Université de Sherbrooke (MSc) and a **Ph.D. at McMaster University**, before joining for his post-doctoral training in the field of embryonic stem cells at the NIH – NICHD in Bethesda, Maryland. He joined McGill U in 1992 and served as **Director of the McGill Cancer Centre/Goodman Centre** from 2000 to 2012, after which he stepped down to dedicate his efforts full-time to academic research. Dr. Tremblay's

laboratory uses biochemical and genetic approaches to characterize the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family. He has filed over 30 patents and **nearly 25000 citations** from **over 250 published or submitted publications**, leading to a **GS H-Index of 83**. He is recognized worldwide for his work with this gene family and its function in cancer, diabetes, and neuroscience. In 2012, he completed a one-year sabbatical at the Immunology Frontier Research Center at Osaka University, Osaka, Japan.

Dr. Tremblay has served on several scientific boards of foundations and companies, including three companies, that he founded. He continues to be involved with two of them, **MISPRO Biotech Inc. and Kanyr Pharma Inc.** He was a member of the Executive Committee of the Fonds de Recherche en Santé du Québec (FRSQ) and a coordinator of the Quebec node of the Terry Fox Research Institute. He was also a member of the first Scientific Committee of the CQDM. He was elected and joined McGill University's Senate from 2017-2019. In 2018, he was a **co-founder and the first director of the McGill Regenerative Medicine Network at McGill University** until Dec. 2021 (<https://mrm.research.mcgill.ca>). A recipient of an FRSQ National Scientist Award, Dr. Tremblay was named Fellow in 2007, Chair of the Life Science Division (2015-2020) at the Royal Society of Canada, and he is currently **President of the Academy of Sciences of the Royal Society of Canada (2022-2025)**. As a volunteer, he acted as Chair of the scientific committee of the Cancer Research Society and on the ACOR committee of the Canadian Cancer Society. On the international scene, he was a member of the Scientific Advisory Board of the International Mouse Phenotyping Consortium until 2021 and served on the Luxemburg Health Institute Oncology advisory committee.

Through the years, he has obtained several awards and prizes: These include the **Michel-Sarrazin Prize (2012)** from the Quebec Clinical Research Club, the **Robert L. Noble Prize for outstanding achievement** in cancer research by the Canadian Cancer Society, the celebrated "**Prix Armand-Frappier**" 2013, a "Prix du Québec" for his contribution to the advancement of science and the building of a research institution. Given these actions, the Quebec Government named him "**Knight of the Order of Quebec**" in June 2015. Michel L. Tremblay received the prestigious **2017 McLaughlin medal** from the Royal Society of Canada for sustained excellence in his medical science research. In recognition of his services to McGill University, he was also honored in April 2018 by receiving the status of **Distinguished James McGill Professor**, and from his Alma Mater of U. of Sherbrooke the **title of Grand Ambassador** on May 2nd, 2019. In the fall of 2021, he received a second Prix du Québec – the "**Walter-Penfield prize**" for his career's contribution in the field of Protein Tyrosine Phosphatases. Recently, he was awarded an **Honoris Causa Doctorate from the Université de Bordeaux** (May 2022) for his sustained work in biomedical research and his work on the protein tyrosine phosphatases.